![Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei]](/content/dam/biopharm/esperoct/global/esperoct-logo.png){kind=logo}
The Esperoct® EHL formula ensures that factor stays in your body longer—in fact, 60% longer than SHL products in adults and up to 85% longer in children.b,c
Extend half-life beyond the standard.
With Esperoct®, factor VIII levels stay high—longer.a
aCompared with standard half-life products.
Extend half-life beyond the standard.
With Esperoct®, factor VIII levels stay high—longer.a
aCompared with standard half-life products.
Extended half-life (EHL) vs standard half-life (SHL).
In adults.
In children <12 years old.
bData shown are from a comparison study of 26 previously treated patients (PTPs) 18 years or older who received a 25, 50, or 75 IU/kg dose of their previous SHL product followed by the same dose of Esperoct®. To allow for comparison, all results were adjusted to a 50 IU/kg dose of each product.
cComparison to prior FVIII product was performed at the beginning of the study in previously treated children. Esperoct® half-life was 14.7 hours in 12 children ages 0–5 and 13.8 hours in 10 children 6–11.
dData shown are from 42 adults who received a pharmacokinetic (PK) assessment around the first Esperoct® 50 IU/kg dose.
eComparison to prior FVIII product was performed at the beginning of the study in previously treated children. The geometric mean terminal half-life in 23 children aged 0-<12 years was 14.3 hours. Esperoct® geometric mean terminal half-life was 14.7 hours in 12 children ages 0–5 and 13.8 hours in 10 children ages 6-11.
What is half-life?
Half-life is the time it takes for the level of factor in the blood to fall by half.
What is half-life?
Half-life is the time it takes for the level of factor in the blood to fall by half.
What is the difference between standard half-life factor VIII and Esperoct®?
Esperoct® is made by taking the existing factor VIII molecule and adding PEGylation technology to extend the product’s half-life.
A switch from standard half-life treatment—to Esperoct® means factor levels remain high from one dose to the next.
PEGylation explained.
When polyethylene glycol chains—or PEG—attach to a drug’s molecule, the process is called PEGylation. The effect of PEGylation is to extend the useful half–life of the product.
Start with the factor VIII molecule
Standard half-life factor VIII molecules are made up of various elements, including proteins and polypeptides.
Add the PEG technology
Attaching a PEG molecule to the factor VIII polypeptide extends the time it takes the body to clear the factor. We call the resulting extended half-life factor Esperoct®.
Fewer infusions a year.
If your factor VIII product lasts longer—like Esperoct® does—you won’t need to infuse as often, saving time in your busy schedule. Ready to learn about beginning treatment?
More questions about EHL?
You have a great resource in your regional Hemophilia Community Liaison (HCL), who can answer questions about extended half-life, PEGylation, and anything else Esperoct® related.
Support for your life with hemophilia.
Living with hemophilia is about more than treatment. Sign up for our emails to receive bleeding disorder tips and community resources—as well as product updates and information.
Your questions, answered.
Question: Why is knowing a product’s half-life important?
Answer: Measuring a factor’s half-life gives doctors, patients and caregivers the opportunity to compare the factor activity level of different products by calculating the time it takes the body to metabolize or inactivate half the amount of factor.
How long factor stays in the blood, however, is only half the battle. The other consideration is the factor level. The extended half-life of Esperoct® offers higher factor levels for longer compared to standard half-life products.a
Question: Is PEGylation a new process?
Answer: PEGylation is actually a well-established technology that has been used in other treatments for many conditions including hemophilia.